[go: up one dir, main page]

WO2018186650A3 - Double composite tablet for oral administration containing tramadol and celecoxib - Google Patents

Double composite tablet for oral administration containing tramadol and celecoxib Download PDF

Info

Publication number
WO2018186650A3
WO2018186650A3 PCT/KR2018/003905 KR2018003905W WO2018186650A3 WO 2018186650 A3 WO2018186650 A3 WO 2018186650A3 KR 2018003905 W KR2018003905 W KR 2018003905W WO 2018186650 A3 WO2018186650 A3 WO 2018186650A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
celecoxib
tramadol
alleviation
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/003905
Other languages
French (fr)
Korean (ko)
Other versions
WO2018186650A2 (en
Inventor
김승현
황성주
안준현
현상민
곽상원
선보경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kims Healthcare Co Ltd
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Kims Healthcare Co Ltd
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kims Healthcare Co Ltd, Industry Academic Cooperation Foundation of Yonsei University filed Critical Kims Healthcare Co Ltd
Priority to US16/500,311 priority Critical patent/US20200323780A1/en
Priority claimed from KR1020180038579A external-priority patent/KR102033716B1/en
Publication of WO2018186650A2 publication Critical patent/WO2018186650A2/en
Publication of WO2018186650A3 publication Critical patent/WO2018186650A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a double composite tablet for oral administration, comprising: a sustained release layer containing tramadol as an active ingredient; and an immediate release layer containing celecoxib as an active ingredient, wherein the double composite tablet is an oral preparation that is prescribed for alleviation of symptoms or signs of osteoarthritis (degenerative arthritis), alleviation of symptoms or sings of rheumatoid arthritis, alleviation of symptoms or signs of ankylosing spondylitis, relief of acute pain in adults (post-operative or post-extraction pain), primary dysmenorrhea, or severe and moderate acute or chronic pain. Through the present invention, a composition for pain treatment can be provided that reduces side effects of tramadol and has a continuous pain-killing effect for 12 hours by sustainedly releasing tramadol with solubility in water and immediately releasing celecoxib with poor solubility. Furthermore, the number of drugs administered is decreased by preparing two kinds of drugs into a single complex preparation, thereby improving the convenience of drug administration.
PCT/KR2018/003905 2017-04-03 2018-04-03 Double composite tablet for oral administration containing tramadol and celecoxib Ceased WO2018186650A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/500,311 US20200323780A1 (en) 2017-04-03 2018-04-03 Bilayer combination tablet for oral administration containing tramadol and celecoxib

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0042927 2017-04-03
KR20170042927 2017-04-03
KR1020180038579A KR102033716B1 (en) 2017-04-03 2018-04-03 Double composite tablet for oral administration including tramadol and celecoxib
KR10-2018-0038579 2018-04-03

Publications (2)

Publication Number Publication Date
WO2018186650A2 WO2018186650A2 (en) 2018-10-11
WO2018186650A3 true WO2018186650A3 (en) 2019-01-03

Family

ID=63712189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003905 Ceased WO2018186650A2 (en) 2017-04-03 2018-04-03 Double composite tablet for oral administration containing tramadol and celecoxib

Country Status (1)

Country Link
WO (1) WO2018186650A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521292A (en) * 2020-04-15 2021-10-22 江苏恒瑞医药股份有限公司 Compound preparation of COX-2 inhibitor and tramadol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120089287A (en) * 2009-10-16 2012-08-09 라보라토리오스 델 드라. 에스테브.에스.에이. Composition comprising tramadol and celecoxib in the treatment of pain
KR101710792B1 (en) * 2015-07-14 2017-02-28 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and tramadol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120089287A (en) * 2009-10-16 2012-08-09 라보라토리오스 델 드라. 에스테브.에스.에이. Composition comprising tramadol and celecoxib in the treatment of pain
KR101710792B1 (en) * 2015-07-14 2017-02-28 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and tramadol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KODAM, DEEPTHI ET AL.: "Formulation and Evaluation of Tramadol Hydrochloride Sustained Matrix Tablets", SCHOLARS RESEARCH LIBRARY, DER PHARMACIO LETTER, vol. 3, no. 3, 2011, pages 245 - 249, XP055560093 *
RAO, P. SAMBA SIVA ET AL.: "Formulation and Evaluation of Tramadol Hcl Sustained Released Pellets", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, vol. 5, no. 3, 2015, pages 413 - 419, XP055560101 *
REHMAN, ASIM.UR ET AL.: "Formulation and Evaluation of Tramadol HCL Matrix Tablets Using Carbopol 974P and 934 as Rate-controlling Agents", TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 12, no. 2, 2013, pages 169 - 172, XP055560103 *

Also Published As

Publication number Publication date
WO2018186650A2 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
HRP20210618T1 (en) Increasing drug bioavailability in naltrexone therapy
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2010098627A3 (en) Pharmaceutical preparation
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
WO2012035561A3 (en) Improved oral targetted drug delivery system
HRP20190891T1 (en) MEDICAL PRODUCT AND TREATMENT
WO2018186650A3 (en) Double composite tablet for oral administration containing tramadol and celecoxib
JP2012505830A5 (en)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
PH12014502836B1 (en) Medicament form for release of active ingredients
MX2022013541A (en) Gamma-polyglutamic acid and zinc compositions.
IL300144A (en) Fused benzazepines for treatment of tourette's syndrome
JP2019529559A5 (en)
MY187270A (en) Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
WO2015166419A3 (en) Production method and sublingual pharmaceutical composition of ketorolac tromethamine and tramadol hydrochloride used for pain
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
CN102949383A (en) Anti-inflammatory and analgesic drug combination
MX386908B (en) MODIFIED RELEASE FORMULATION OF NAPROXEN SODIUM.
MXPA06000760A (en) Stable pharmaceutical composition containing carisoprodol and meloxicam.
MX2017009660A (en) Pharmaceutical composition with a range of ratio between tramadol chlorhydrate and etoricoxib for its administration for the treatment of pain.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18780409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18780409

Country of ref document: EP

Kind code of ref document: A2